ArTS Archivio della ricerca di Trieste

ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.252
EU - Europa 3.495
AS - Asia 2.553
SA - Sud America 340
AF - Africa 50
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.704
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.190
PL - Polonia 1.715
SG - Singapore 1.042
CN - Cina 651
IT - Italia 405
HK - Hong Kong 345
SE - Svezia 342
BR - Brasile 283
DE - Germania 182
VN - Vietnam 150
RU - Federazione Russa 130
UA - Ucraina 127
FI - Finlandia 117
TR - Turchia 107
GB - Regno Unito 101
IE - Irlanda 78
BG - Bulgaria 72
FR - Francia 71
IN - India 53
NL - Olanda 48
CA - Canada 33
KR - Corea 28
AR - Argentina 27
JP - Giappone 25
MA - Marocco 22
IQ - Iraq 21
MY - Malesia 21
ES - Italia 20
MX - Messico 20
BE - Belgio 18
AT - Austria 14
IL - Israele 14
PK - Pakistan 14
ID - Indonesia 11
BD - Bangladesh 9
CH - Svizzera 9
AE - Emirati Arabi Uniti 8
EC - Ecuador 8
IR - Iran 8
SA - Arabia Saudita 8
CL - Cile 7
JO - Giordania 7
GR - Grecia 6
TN - Tunisia 6
TW - Taiwan 6
UZ - Uzbekistan 6
AU - Australia 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
MD - Moldavia 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
RO - Romania 5
ZA - Sudafrica 5
CO - Colombia 4
JM - Giamaica 4
KE - Kenya 4
NO - Norvegia 4
PY - Paraguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
EG - Egitto 3
LT - Lituania 3
NP - Nepal 3
SI - Slovenia 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
DK - Danimarca 2
EE - Estonia 2
HN - Honduras 2
OM - Oman 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
VE - Venezuela 2
BB - Barbados 1
BH - Bahrain 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SN - Senegal 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 13.704
Salva come PNG Salva come JPEG
Città #
Warsaw 1.642
Fairfield 1.006
Ashburn 759
Singapore 622
Woodbridge 605
Houston 520
Wilmington 445
Seattle 427
Chandler 424
Ann Arbor 401
Cambridge 385
Hong Kong 333
Beijing 205
Jacksonville 185
Santa Clara 173
Trieste 162
Princeton 143
Boardman 122
Columbus 95
Izmir 94
Dallas 80
Dublin 78
Hefei 76
Sofia 71
Los Angeles 64
Moscow 63
Zgierz 59
San Diego 56
Munich 51
Helsinki 50
Ho Chi Minh City 40
Dearborn 37
New York 37
Buffalo 35
Dong Ket 34
The Dalles 34
Bremen 32
Frankfurt am Main 32
London 25
Redwood City 25
Hanoi 24
São Paulo 22
Chicago 21
Turku 21
Phoenix 18
Seoul 18
Tianjin 18
Nuremberg 17
Orem 17
Brussels 16
Casablanca 16
Dongguan 16
Tokyo 16
San Jose 15
San Francisco 14
Duino-Aurisina 13
Falls Church 13
Mumbai 13
Nanjing 13
Lappeenranta 12
Shanghai 12
Denver 11
Kunming 11
Milan 11
Montegaldella 11
Poplar 11
Toronto 11
Düsseldorf 10
Guangzhou 10
Jinan 10
Norwalk 10
Redondo Beach 10
Amsterdam 9
Atlanta 9
Boston 9
Chennai 9
Fremont 9
Tel Aviv 9
Udine 9
Hangzhou 8
Rio de Janeiro 8
Amman 7
Changsha 7
Decatur 7
Des Moines 7
Eagan 7
Florence 7
Montreal 7
Pignone 7
Portsmouth 7
Redmond 7
Roubaix 7
Shenyang 7
Ankara 6
Brooklyn 6
Lahore 6
Nanchang 6
New Delhi 6
Padova 6
Rho 6
Totale 10.393
Salva come PNG Salva come JPEG
Nome #
Advances in systemic therapy for metastatic breast cancer: future perspectives 383
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 360
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 342
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 340
Isolated testicular metastasis from prostate cancer 339
Bevacizumab in small cell lung cancer 328
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 320
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 319
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 305
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 305
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 284
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 270
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 258
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 256
Corticosteroid switch after progression on abiraterone acetate plus prednisone 256
Advances in systemic therapy for malignant mesothelioma: Future perspectives 239
Apatinib for the treatment of gastric cancer 232
Lenvatinib for the treatment of renal cell carcinoma 225
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 215
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 213
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 213
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 205
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 201
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? 201
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 195
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 194
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 193
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 184
Tumour Infiltrating Lymphocytes and Immune-Related Genes as Predictors of Outcome in Pancreatic Adenocarcinoma 183
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 181
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 180
Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies before and after Chemotherapy 179
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 173
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 171
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 168
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 163
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 160
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 153
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 153
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials 150
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 148
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 144
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 142
Familial aggregation of gastric cancer with microsatellite instability** 141
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 141
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience 140
Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? 138
Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel 137
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 131
Avelumab in gastric cancer 129
Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification 129
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 127
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 127
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 126
Apatinib in metastatic gastric cancer: Can paclitaxel make the difference? 126
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials 125
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies? 123
Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient 121
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 121
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 119
Is it time for everolimus-based combination in castration-resistant prostate cancer? 119
Expanding treatment options for metastatic gastric cancer 117
Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis 114
Surgical management of advanced gastric cancer: An evolving issue 113
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives 112
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 111
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients 99
Cancer management during the COVID-19 world pandemic 99
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies 97
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis 95
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer 92
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature 89
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 88
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue 86
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer 86
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials 83
Immune-gene signature: A new tool for patient selection for checkpoint inhibitors? 69
P53 antibodies as a diagnostic marker for cancer: A meta-analysis 61
Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies 60
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study 51
Effects of Whole Pelvic Radiotherapy on the Distribution of Lymphocyte Subpopulations in Prostate Cancer Patients 51
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When 50
DNA repair deficiency as circulating biomarker in prostate cancer 36
Totale 14.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.622
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021887 0 0 0 0 0 0 202 170 111 191 71 142
2021/2022858 78 76 58 40 8 70 53 33 130 118 61 133
2022/20231.260 109 145 131 185 113 213 14 104 160 14 46 26
2023/2024773 36 83 45 56 34 74 141 153 2 42 50 57
2024/20252.227 27 200 377 134 171 294 101 85 261 215 189 173
2025/20261.915 415 195 181 341 405 345 33 0 0 0 0 0
Totale 14.002